Latest news
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $50 - MoomooMoomoo · Fri, 07 Aug 2026 03:51:33 GMTVeracyte (NASDAQ:VCYT) Growth Story Gains Fresh Market Attention - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 15:52:00 GMTVCYT Maintained by Piper Sandler -- Price Target Lowered to $54. - GuruFocusGuruFocus · Tue, 04 Aug 2026 17:58:01 GMTVCYT Maintained by Morgan Stanley -- Price Target Lowered to $44 - GuruFocusGuruFocus · Tue, 04 Aug 2026 16:41:15 GMTVCYT Maintained by Stephens & Co. -- Price Target Lowered to $55 - GuruFocusGuruFocus · Tue, 04 Aug 2026 15:09:25 GMTVCYT Maintained by Canaccord Genuity -- Price Target Lowered to $50 - GuruFocusGuruFocus · Tue, 04 Aug 2026 02:36:43 GMTVeracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests - simplywall.stsimplywall.st · Tue, 04 Aug 2026 00:56:15 GMTCanaccord cuts Veracyte stock price target to $50 on revenue outlook - Investing.com IndiaInvesting.com India · Mon, 03 Aug 2026 22:22:59 GMT